Spectrum Pharmaceuticals seeks FDA approval for ROLONTIS to combat chemotherapy-induced neutropenia
In a significant move within the oncology sector, Spectrum Pharmaceuticals has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) ... Read More
Teva launches generic version of Elidel Cream to expand eczema treatment options
Teva Pharmaceutical Industries has unveiled its generic version of Elidel (pimecrolimus) Cream, 1%, providing a more affordable treatment option for individuals battling mild to moderate ... Read More
FDA accepts review of Kala Pharmaceuticals’ new dry eye treatment KPI-121 0.25%
The United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for KPI-121 0.25%, an investigational treatment developed by Kala Pharmaceuticals ... Read More
Vedanta Biosciences secures $27m to propel microbiome drug pipeline
US-based Vedanta Biosciences has raised $27 million in a Series C financing round to accelerate its pioneering work on microbiome-derived therapeutics. The funding round attracted ... Read More
Lupin collaborates with AbbVie for $977m MALT1 inhibitor program targeting hematological cancers
Indian pharmaceutical company Lupin has entered a landmark agreement to out-license its MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program to US-based biopharmaceutical ... Read More
Novartis aims to strengthen cell therapy capabilities with CellforCure acquisition
Novartis has announced plans to acquire CellforCure, a French contract development and manufacturing organisation (CDMO), from LFB for an undisclosed amount. The deal underscores the ... Read More
Amgen submits BLA for Infliximab biosimilar ABP 710 to FDA
Amgen Inc. has officially submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to ... Read More
Innovent Biologics and Incyte announce $391.5m partnership for cancer drugs in China
Innovent Biologics, a leading Chinese biopharma company, has struck a landmark deal with Incyte, a prominent US pharmaceutical firm, to develop and commercialize three investigational ... Read More
Astellas Pharma acquires Potenza Therapeutics in $404.7m deal
Japanese pharmaceutical giant Astellas Pharma has announced the acquisition of US-based Potenza Therapeutics in a significant transaction valued at up to $404.7 million. This strategic ... Read More
FDA greenlights Amgen’s Nplate for pediatric immune thrombocytopenia
Amgen’s Nplate (romiplostim) has received US Food and Drug Administration (FDA) approval for treating pediatric patients with immune thrombocytopenia (ITP). This latest approval extends the ... Read More